Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Global Data has revealed that the Top 20 Global Biopharmaceutical Companies have witnessed a 6 % growth in market ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Wall Street’s Evan David Seigerman stirred the pot by slashing his price target on Eli Lilly stock—but not his enthusiasm.

West Pharmaceutical Services raised its annual profit forecast on Thursday, anticipating a boost from a weaker dollar to ...

Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Receiving a generic version of Ozempic or Wegovy from a compounding pharmacy is normally both easier to access and cheaper.

Glucagon-like peptide 1 receptor agonists, which are found in Ozempic-like drugs, can could cause devastating symptoms in ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.